Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer’s disease patients on11C-N-methyl-4-piperidyl benzilate — Comparison with cerebral blood flow and cerebral glucose metabolism

• Published in: Annals of nuclear medicine Vol. 12; no. 1; pp. 35 - 42
• Main Authors: Yoshida, Tsuyoshi, Kuwabara, Yasuo, Ichiya, Yuichi, Sasaki, Masayuki, Fukumura, Toshimitsu, Ichimiya, Atsushi, Takita, Masashi, Ogomori, Koji, Masuda, Kouji
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Nature B.V 01.02.1998
• Subjects: Alzheimer's disease; Brain
• ISSN: 0914-7187; 1864-6433
• DOI: 10.1007/BF03165414

We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of^sup 11^C-N- methyl-4-piperidyl benzilate (^sup 11^C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having "probable AD" and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by^sup 99m^Tc-HMPAO SPECT, and the CMRGlc was measured by^sup 18^FDG PET. The^sup 11^C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mACh-R decrease and more severe CMRGlc decrease in the cortical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the^sup 18^FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.[PUBLICATION ABSTRACT]